Joanne Kurtzberg1. 1. The Pediatric Blood and Marrow Transplant Program, The Carolinas Cord Blood Bank, Duke University Medical Center, Durham, North Carolina 27705, USA. kurtz001@mc.duke.edu
Abstract
PURPOSE OF REVIEW: 2008 marks the 20th anniversary of the first use of umbilical cord blood (UCB) as a source of donor cells for hematopoietic stem cell transplantation. In those early days, there was great doubt and skepticism about the utility of UCB as a source of hematopoietic stem cells. Doubts about whether UCB, containing 10-20x fewer cells than bone marrow, had sufficient cells to durably engraft a myeloablated patient and, after demonstration that engraftment occurred with less graft-versus-host disease, whether it would confer graft-versus-leukemia activity were raised. RECENT FINDINGS: Transplantation with UCB is effective in the treatment of children with hematological malignancies, marrow failure, immunodeficiencies, hemoglobinopathies and inherited metabolic diseases. Transplantation without full human leukocyte antigen matching is possible and, despite a lower incidence of graft-versus-host disease, graft-versus-leukemia is preserved. The number of cells in a single UCB can be limiting, but the use of two UCBs for a single transplant shows promise to overcome this obstacle. SUMMARY: Cord blood transplantation is now an established field with enormous potential. UCB increases access to transplantation therapy for many patients unable to identify a fully matched adult donor. In the future, it may emerge as a source of cells for cellular therapies focused on tissue repair and regeneration.
PURPOSE OF REVIEW: 2008 marks the 20th anniversary of the first use of umbilical cord blood (UCB) as a source of donor cells for hematopoietic stem cell transplantation. In those early days, there was great doubt and skepticism about the utility of UCB as a source of hematopoietic stem cells. Doubts about whether UCB, containing 10-20x fewer cells than bone marrow, had sufficient cells to durably engraft a myeloablated patient and, after demonstration that engraftment occurred with less graft-versus-host disease, whether it would confer graft-versus-leukemia activity were raised. RECENT FINDINGS: Transplantation with UCB is effective in the treatment of children with hematological malignancies, marrow failure, immunodeficiencies, hemoglobinopathies and inherited metabolic diseases. Transplantation without full human leukocyte antigen matching is possible and, despite a lower incidence of graft-versus-host disease, graft-versus-leukemia is preserved. The number of cells in a single UCB can be limiting, but the use of two UCBs for a single transplant shows promise to overcome this obstacle. SUMMARY: Cord blood transplantation is now an established field with enormous potential. UCB increases access to transplantation therapy for many patients unable to identify a fully matched adult donor. In the future, it may emerge as a source of cells for cellular therapies focused on tissue repair and regeneration.
Authors: Maria L Escolar; Michele D Poe; James M Provenzale; Karen C Richards; June Allison; Susan Wood; David A Wenger; Daniel Pietryga; Donna Wall; Martin Champagne; Richard Morse; William Krivit; Joanne Kurtzberg Journal: N Engl J Med Date: 2005-05-19 Impact factor: 91.245
Authors: A Bhattacharya; M A Slatter; C E Chapman; D Barge; A Jackson; T J Flood; M Abinun; A J Cant; A R Gennery Journal: Bone Marrow Transplant Date: 2005-08 Impact factor: 5.483
Authors: Donna A Wall; Shelly L Carter; Nancy A Kernan; Neena Kapoor; Naynesh R Kamani; Joel A Brochstein; Haydar Frangoul; Rakesh K Goyal; John T Horan; Daniel Pietryga; John E Wagner; Joanne Kurtzberg Journal: Biol Blood Marrow Transplant Date: 2005-08 Impact factor: 5.742
Authors: Paul L Martin; Shelly L Carter; Nancy A Kernan; Indira Sahdev; Donna Wall; Daniel Pietryga; John E Wagner; Joanne Kurtzberg Journal: Biol Blood Marrow Transplant Date: 2006-02 Impact factor: 5.742
Authors: Mary Eapen; Pablo Rubinstein; Mei-Jie Zhang; Cladd Stevens; Joanne Kurtzberg; Andromachi Scaradavou; Fausto R Loberiza; Richard E Champlin; John P Klein; Mary M Horowitz; John E Wagner Journal: Lancet Date: 2007-06-09 Impact factor: 79.321
Authors: Suhag H Parikh; Paul Szabolcs; Vinod K Prasad; Sonali Lakshminarayanan; Paul L Martin; Timothy A Driscoll; Joanne Kurtzberg Journal: Pediatr Blood Cancer Date: 2007-12 Impact factor: 3.167
Authors: J J Boelens; R F Wynn; A O'Meara; P Veys; Y Bertrand; G Souillet; J E Wraith; A Fischer; M Cavazzana-Calvo; K W Sykora; P Sedlacek; A Rovelli; C S P M Uiterwaal; N Wulffraat Journal: Bone Marrow Transplant Date: 2007-05-28 Impact factor: 5.483
Authors: Alicia Bárcena; Marcus O Muench; Mirhan Kapidzic; Matthew Gormley; Gabriel A Goldfien; Susan J Fisher Journal: Transfusion Date: 2011-11 Impact factor: 3.157
Authors: Jaichandran Sivalingam; Shruti Krishnan; Wai Har Ng; Sze Sing Lee; Toan Thang Phan; Oi Lian Kon Journal: Mol Ther Date: 2010-04-27 Impact factor: 11.454